SPOC1, a novel PHD-finger protein: Association with residual disease and survival in ovarian cancer

International Journal of Cancer

Volumn 116, Issue 4, 2005, Pages 547-554

  Mohrmann, Gerrit ^a,b   Hengstler, Jan G ^c   Hofmann, Thomas G ^b   Endele, Sabine U ^a,b   Lee, Brendan ^d   Stelzer, Christiane ^e   Zabel, Bernhard ^e   Brieger, Juergen ^f   Hasenclever, Dirk ^c   Tanner, Berno ^e   Sagemueller, Jens ^c   Sehouli, Jalid ^g   Will, Hans ^b   Winterpacht, Andreas ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ovarian cancer; PHD finger; Survival time; Transcription

Indexed keywords

GENE PRODUCT; PLANT HOMEODOMAIN FINGER PROTEIN; PROTEIN SPOC1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL TYPE; CHROMOSOME 1P; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENETIC TRANSCRIPTION; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SPERMATOCYTE; SPERMATOGONIUM; SPOC1 GENE; SURVIVAL TIME;

AGED; AMINO ACID SEQUENCE; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOGLYCANS; RNA, MESSENGER; SPERMATOGONIA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 23244442237     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20912     Document Type: Article

References (51)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
2. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. Philadelphia: Lippincott-Raven, 1997, 1502-39.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
4. Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W. NOGGO study group. A phase 11 study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002;13:1749-55.
5. Kozlova NI, Morozevich GE, Chubukina AN, Shtil AA, Berman AE. Expression of integrins, anchorage dependent apoptosis and invasiveness of inultidrug resistant human breast carcinoma cells. EXCL1 J 2004;3:68-81.
6. Brenner W, Wiesner C, Färber G, Herget T, Hengstler JG, Thüroff JW. Gender specific expression of tumor suppressor PKCd versus oncogenic PKCh in renal cell carcinoma. EXCLI J 2003;2:45-51.
7. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.
8. Hellstrom I, Rayerait J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
9. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66-73.
10. Tanner B, Hengstler JG, Laubscher S, Meinert R, Oesch F, Knapstein PG, Becker R. MDM2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997;74:1-5.
11. Tanner B, Grimme S, Schiffer I, Heimerdinger C, Schmidt M, Dutkowski P, Neubert S, Oesch F, Franzen A, Kolbl H, Fritz G, Kaina B, Hengstler JG. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas. Gynecol Oncol 2004;92:568-77.
12. Konstantinidou AE, Korkolopoulou P, Vassilopoulos I, Tsenga A, Thymara I, Agapitos E, Patsouris E, Davaris P. Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecol Oncol 2003;88:369-78.
13. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003;88:816-221.
14. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
15. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
16. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003;21:285-91.
17. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43.
18. Herrmann F, Lehr HA, Drexler I, Sutler G, Hengstler J, Wollscheid U, Seliger B. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004;64: 215-20.
19. Schiffer IB, Gebhard S, Heimerdinger CK, Heling A, Hast J, Wollseheid U, Seliger B, Tanner B, Gilbert S, Beckers T, Baasner S, Brenner W, et al. Switching off her-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res 2003;63:7221-31.
20. Hengstler JG, Lange J, Kelt A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B. Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.
21. 6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. Int J Cancer 1999;84:388-95.
22. Aasland R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 1995;20:56-9.
23. Capili AD, Schultz DC, Rauscher IF, Borden KL. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO J 2001;20:165-77.
24. Ragvin A, Valvatne H, Erdal S, Arskog V, Tufteland KR, Breen K, Oyan AM, Eberharter A, Gibson TJ, Becker PB, Aasland R. Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. J Mol Biol 2004;337:773-88.
25. Bochar DA, Savard J, Wang W, Lafleur DW, Moore P, Cote J, Shiekhattar R. A family of chromatin remodeling factors related to Williams syndrome transcription factor. Proc Natl Acad Sci USA 2000;97:1038-43.
26. ING1 are associated with histone acetyltransferase activities. Mol Cell Biol 2000;20:3807-16.
27. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol 2002;4:367-73.
28. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC. A novel PHD-finger motif protein. p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003;22:343-50.
29. Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S. Nishizaki K, Shimizu K. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 2000;60:3143-6.
30. Jacobson S, Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 1999;9:175-84.
31. Madsen B, Spencer-Dene B, Poulsom R, Hall D, Lu PJ, Scott K, Shaw AT, Burchell JM, Freemont P, Taylor-Papadimitriou J. Characterisation and developmental expression of mouse Plu-1. a homologue of a human nuclear protein (PLU-1) which is specifically upregulated in breast cancer. Gene Expr Patterns 2002;2:275-82.
32. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, Sugano S, Nakamura Y, Inazawa J. Identification of a novel gene. GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000;60:4735-9.
33. Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001;74:79-88.
34. Chen L, Matsubara N, Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y, Naomoto Y, Isozaki H, Riabowol K, Tanaka N. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res 2001;61:4345-9.
35. Czemobilski B. Blaustein's pathology of the female genital tract. New York: Springer, 1987, 560-607.
36. Vlachtsis K, Brieger J, Kim DW, Gieringer R, Hast J, Hengstler JG, Mann W. Quantitative analysis of VEGF-isoforms in head and neck squamous cell carcinoma cell lines: relation to xenotransplantability and tumor progression in mice. Oncol Rep 2002;9:1133-8.
37. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
38. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R. C-erbB-2 expression in small cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-9.
39. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-94.
40. Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemüller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B. Metallothionein expression in ovarian cancer in relation to histopathologic parameters and molecular markers of prognosis. Int J Cancer 2001;95:121-7.
41. Thompson FH, Taetle R, Trent JM, Liu Y, Massey-Brown K, Scott KM, Weinstein RS, Emerson JC, Alberts DS, Nelson MA. Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet Cytogenet 1997;96:106-10.
42. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL. Evidence for a rare prostate cancer-susceptibility locus at chromosome lp36. Am J Hum Genet 1999;64:776-87.
43. Imyanitov EN, Birrell GW, Filippovich I, Sorokina N, Arnold J, Mould MA, Wright K, Walsh M, Mok SC, Lavin MF. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 1999;18:4640-2.
44. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumors: association with survival. Br J Cancer 1999;79:1468-74.
45. Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, Takayasu H, Islam A, Nakamura Y, Takahashi M. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene 2000;19: 4302-7.
46. Alvarez AA, Lambers AR, Lancaster JM, Maxwell GL, Ali S, Gumbs C, Berchuck A, Futreal PA. Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol 2001;82:94-8.
47. Taetle R, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 1999;25:290-300.
48. Rao PH, Harris CP, Yan Lu X, Li XN, Mok SC, Lau CC. Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 2002;33:123-32.
49. Aravind L, Iyer LM, Koonin EV. Scores of RINGS but no PHDs in ubiquitin signaling. Cell Cycle 2003;2:123-6.
50. Gibbons RJ, Bachoo S, Picketts DJ, Aftimos S, Asenbauer B, Bergoffen J, Berry SA, Dahl N, Fryer A, Keppler K. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat Genet 1997;17:146-8.
51. Tanner B, Hengstler JG, Luch A, Meinen R, Kreutz E, Arand M, Wilkens C, Hofmann M, Oesch F, Knapstein PG, Becker R. c-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type. Int J Gynecol Pathol 1998;17:66-74.